Mr. Stephen Lockyer reports

MEDX HEALTH CORP. ANNOUNCES AMENDED APPLICATION FOR SERIES I LOAN NOTE EXTENSION

Further to MedX Health Corp.'s press release dated Aug. 6, 2024, the TSX Venture Exchange issued a final acceptance letter dated Aug. 14, 2024, in respect of the amendment to the remaining outstanding $3.7-million of the Series I loan notes issued in 2021, by the extension of the maturity date from Dec. 31, 2023, to Dec. 31, 2025, but has since withdrawn that final acceptance. The company is now filing an application for a revised final acceptance of the extension of the maturity date for the Series I loan notes, only in respect of $2.65-million of Series I loan notes in respect of which extension agreements have been signed. In the event that any of the holders of Series I loan notes who have not yet signed extension agreements do decide to accept the extension, then the company may submit request(s) to the TSX-V for acceptance, issuance of which will be subject to applicable TSX-V policies.

Included among the holders of Series I loan notes who have agreed to the extension, and holding a total value of $150,000, are two related parties as such term is defined by Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions (MI 61-101). In connection with the extension of the maturity date on the Series I loan notes, the company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Section 5.7(1)(a) of MI 61-101.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its Siascopy on DermSecure telemedicine platform, utilizing its Siascopy technology. Siascopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485 certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.